SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. A webcast of the on demand presentation will be accessible by visiting the Presentation & Events section on the ...

SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best- in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company fo ...

文章核心观点 Aligos Therapeutics公司管理层将于2025年6月5日下午2点在杰富瑞全球医疗保健会议上进行展示 [1] 会议信息 - 会议为杰富瑞全球医疗保健会议 [1] - 时间为2025年6月5日下午2点（美国东部时间） [1] - 展示将进行网络直播，可通过公司网站“投资者”页面的“展示与活动”部分访问 [2] - 直播回放将在展示结束后至少30天内提供 [2] 公司介绍 - 公司是临床阶段的生物制药公司 [1][3] - 使命是通过开发一流疗法改善肝脏和病毒疾病患者的治疗效果 [1][3] - 运用科学驱动方法和深厚研发专业知识推进针对慢性乙肝病毒感染、代谢功能障碍相关脂肪性肝炎和冠状病毒等未满足医疗需求的治疗药物管线 [3] 联系方式 - 投资者关系与企业传播副总裁Jordyn Tarazi 电话+1 (650) 910-0427 邮箱jtarazi@aligos.com [6] - 媒体联系人Inizio Evoke的Jake Robison 邮箱Jake.Robison@inzioevoke.com [6] 更多信息获取途径 - 可访问公司网站www.aligos.com 或在领英和X上关注公司 [4]